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Abstract
A risk score for AF has been developed by the Framingham Heart Study; however the
applicability of this risk score, derived from whites, to predict new-onset AF in non-whites is
uncertain. Therefore, we developed a 10-year risk score for new-onset AF using risk factors
commonly measured in clinical practice using 14,546 individuals from the Atherosclerosis Risk in
Communities study, a prospective community-based cohort of blacks and whites in the United
States. During 10 years of follow-up, 515 incident AF events occurred. The following variables
were included in the AF risk score: age, race, height, smoking status, systolic blood pressure,
hypertension medication usage, precordial murmur, left ventricular hypertrophy, left atrial
enlargement, diabetes, coronary heart disease, and heart failure. The area under the receiver-
operating characteristics curve (AUC) of a Cox regression model including the previous variables
was 0.78, suggesting moderately good discrimination. The point-based score developed from
coefficients in the Cox model had an AUC of 0.76. This clinical risk score for AF in the ARIC
cohort compared favorably with the Framingham Heart Study’s AF (AUC=0.68), CHD
(AUC=0.63), and hard CHD (AUC=0.59) risk scores and the ARIC CHD risk score (AUC=0.58).
In conclusion, we have developed a risk score for AF and have shown that the different
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pathophysiologies of AF and CHD limit the usefulness of a CHD risk score at identifying
individuals at higher risk of AF.
Keywords
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INTRODUCTION
Risk factors for AF include increasing age, male gender, obesity, hypertension, diabetes, and
cardiac structural abnormalities, such as increased left ventricular wall thickness.1 While the
relationship between some of the above mentioned risk factors with incident AF have been
well studied on a population level, formulae for predicting a person’s individual risk of AF
are scarce. A risk score for AF has been recently developed by the Framingham Heart Study.
2 The discrimination of the Framingham risk score was good for whites (C statistic=0.78);
however, its utility to predict 10-year risk of developing AF in non-whites is uncertain. This
is particularly relevant given the lower risk of AF among blacks.3, 4 Therefore, we aimed to
develop a risk score for predicting AF incidence based on risk factors that can be easily
assessed in clinical practice using a cohort of blacks and whites, the Atherosclerosis Risk in
Communities (ARIC) study.
METHODS
The ARIC study is a prospective cohort investigation aimed to identify risk factors for
atherosclerosis and cardiovascular disease. ARIC recruited probability samples of adults
aged 45–64 years from 4 U.S. communities: Forsyth County, North Carolina; Jackson,
Mississippi; Minneapolis suburbs, Minnesota; and Washington County, Maryland.5 Blacks
were over-sampled from Forsyth County and exclusively sampled from Jackson. A total of
15,792 participants (8710 women, 4266 blacks) were enrolled from 1987 to 1989, and
completed a home interview and clinic visit. Three triennial follow-up clinic visits were
conducted (1990–92, 1993–95, 1996–98). In addition, participants are followed-up by
annual telephone interviews (with a >93% response rate) and active surveillance of the
ARIC community hospitals. The ARIC study was approved by institutional review boards at
each participating center, and informed consent was obtained from participants at every
clinic visit.
Electrocardiograms (ECGs) during the baseline visit were used to identify individuals with
prevalent AF or atrial flutter for exclusion. Incident AF diagnoses within 10 years of the
baseline exam were identified from 3 sources: ECGs performed during study follow-up
visits through 1998, and hospital discharge records and death certificates through 10 years of
follow-up.
All ARIC examination ECGs were recorded using MAC PC Personal Cardiographs
(Marquette Electronics, Inc., Milwaukee, WI). A standard supine 12-lead resting ECG was
recorded ≥ 1 hour after smoking tobacco or ingestion of caffeine at each clinic visit. ECGs
were then transmitted by modem to the ARIC ECG Reading Center for computer coding.
ECG recordings during follow-up that were computer coded as AF were visually re-checked
by a cardiologist to confirm the diagnosis.6
Annual follow-up telephone calls were made to cohort participants in order to identify
hospitalizations and deaths. In addition, ARIC community hospitals were surveyed for
potential cardiovascular events. Hospital discharge ICD codes were recorded from all
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hospitalizations, and AF was identified by an ICD-9 discharge code of 427.31 or 427.32
among any of the discharge diagnoses. AF was also identified when any listed cause of
death on a death certificate was coded as AF (ICD-9 code 427.3 or ICD-10 code I48). AF
occurring simultaneously with heart revascularization surgery (ICD-9 code 36.X) or other
cardiac surgery involving heart valves or septa (ICD-9 code 35.X) was not considered an
incident event and follow-up was continued beyond that episode for incident AF not
associated with cardiac surgery. Prior analysis within the ARIC cohort to determine the
validity of hospital discharge diagnoses for AF reported 84% sensitivity and 98% specificity
for the ascertainment of AF.3
Study participants were asked to fast for 12 hours before the clinic visit, during which a
blood sample was obtained and a physical exam was performed. Blood collection and
processing techniques for the ARIC study have been previously described.7 Enzymatic
methods were used to measure total cholesterol (TC) and triglycerides (TG).8 High-density
lipoprotein (HDL) cholesterol was measured enzymatically after dextran sulfate-Mg2+
precipitation of other lipoproteins.9 Low-density lipoprotein (LDL) cholesterol levels were
estimated with the Friedewald formula for individuals with TG levels <400 mg/dL.10 In a
scrub suit and without shoes, standing height and waist circumference (at the level of the
umbilicus) were measured to the nearest centimeter. Body mass index (BMI) was calculated
as weight (in kilograms) divided by height (in meters) squared.
Race, smoking status, and drinking status were determined by self-report. The sports index
for physical activity during leisure time ranged from 1 (low) to 5 (high), and was based on
the questionnaire developed by Baecke et al.11 Blood pressures were measured 3 times in
the sitting position after 5 minutes of rest using a random-zero sphygmomanometer, and the
last 2 measurements were averaged. Participants were asked to bring all medications with
them during clinic visits. A prescription bottle or self-report was used to determine
cholesterol and blood pressure medication use.
The presence of a systolic or diastolic murmur was identified during the physical
examination by a trained clinician using a stethoscope. A resting 12-lead ECG was used to
define the P-R interval and presence of left ventricular hypertrophy (LVH) and left atrial
enlargement (LAE). ECG-diagnosed LVH was considered present if the Cornell voltage was
>28 mm in men or >22 mm in women.12 LAE by ECG was defined as a p-wave duration of
≥ 120 ms.13 A participant was categorized as diabetic if they had a fasting glucose ≥ 126
mg/dL (or non-fasting glucose of ≥200 mg/dL), reported a physician diagnosis of diabetes,
or was currently taking medication for diabetes. Prevalent CHD at baseline included a
history of myocardial infarction (MI), MI adjudicated from the baseline ECG, or history of
coronary bypass or angioplasty. Prevalent HF was identified using the Gothenburg criteria14
or self-report of HF medication use in the past 2 weeks.
All analyses were conducted using SAS version 8.2 (SAS Institute, Cary, NC). For the
development of this risk score, we considered the following variables at baseline: age (45 to
<50 (reference), 50 to <55, 55 to <60, and 60 to 64 years), gender (male, female
(reference)), race (black, white (reference)), BMI (<20, 20 to <25 (reference), 25 to <30,
≥30 kg/m2), height (<164 (reference), 164 to <173, ≥173 cm), waist circumference (<88/
<102 (reference), ≥88/102 cm in men/women), sports score (<2.0, 2.0 to <3.0, 3.0 to <4.0,
≥4.0 (reference)), smoking status (current, former, never (reference)), drinking status
(current, former, never (reference)), systolic blood pressure (<100, 100 to <120 (reference),
120 to <140, 140 to <160, ≥160 mmHg), diastolic blood pressure (<70, 70 to <80
(reference), 80 to <90, 90 to <100, ≥100 mmHg), hypertension medication usage (no
(reference), yes), total cholesterol (<200 (reference), 200 to <240, ≥240 mg/dL), LDL
cholesterol (<100 (reference), 100 to <130, 130 to <160, 160 to <190, ≥190 mg/dL), HDL
Chamberlain et al. Page 3













cholesterol (<40, 40 to <60, ≥60 mg/dL (reference)), triglycerides (<150 (reference), 150 to
<200, ≥200 mg/dL), cholesterol medication usage (no (reference), yes), precordial murmur
(no (reference), yes), heart rate (<60, 60 to <90 (reference), ≥90 beats per minute (bpm)), P-
R interval (<160 (reference), 160 to <200, ≥200 ms), LVH by ECG (no (reference), yes),
LAE by ECG (no (reference), yes), diabetes (no (reference), yes), CHD (no (reference),
yes), and HF (no (reference), yes). Continuous variables were categorized based on clinical
criteria or on the distribution of the variable in the ARIC study.
Of the 15,792 ARIC participants, we excluded those who were not of black or white race
(N=48), blacks from Minneapolis and Washington County (N=55), prevalent AF (N=37) or
missing AF status (N=244) at baseline, those with unreadable ECGs (N=85), and those with
missing values for any variable in our final risk score (N=777). Person-years of follow-up
were computed from the baseline exam until a first AF diagnosis, death, loss to follow-up,
or a follow-up of 10 years, whichever came first. Univariate associations of AF with
potential risk factors were run first using Cox proportional hazards models. Significant
(p<0.10) risk factors from the univariate models were then pooled into 1 multivariate Cox
model and a backwards stepwise elimination was used to identify significant (p<0.10)
predictors in our multivariate model. All possible interactions of risk factors with age and
race were then tested. Interaction tests between risk factors identified in our multivariate
model and log of follow-up time confirmed the proportional hazards assumption was met.
Once the final Cox model was determined, we followed the method used by the
Framingham Heart Study15 to calculate points associated with each level of our risk factors
and to determine the 10-year probability of developing AF by point total. We calculated a
score for all participants in our dataset by calculating a point total based on the risk score.
The discrimination of both the Cox regression model and the actual point-based risk score
was estimated using the area under the receiver-operating characteristics curve (AUC).16
The calibration, a measure of goodness of model fit, was assessed by comparing the
observed and predicted number of AF events in deciles of predicted risk, as calculated by
the Grønnesby-Borgan chi-square statistic.17 We also calculated a point-based score for
participants using the Framingham Heart Study’s AF,2 CHD,18 and hard CHD19 risk scores,
as well as ARIC’s CHD risk score,20, 21 in order to estimate how well these risk scores
predict AF in comparison to our newly developed AF risk score.
Finally, 1000 bootstrap samples were generated, sampling individuals with replacement, in
order to compare our Cox regression model to the point-based score and to conduct an
internal validation of our risk score. Bootstrapping methods provide more stable estimates
with lower bias compared to other methods of internal validation.22 However, since we used
the same cohort to generate the 1000 bootstrap samples for validation of our risk score as we
used to develop the risk score, we adjusted our AUC obtained for the internal validation for
optimism.23
RESULTS
After exclusions, 14,546 individuals remained at risk of AF. During 10 years of follow-up,
515 incident AF events occurred. The baseline characteristics of the study sample, along
with age-, race-, and sex-adjusted hazard ratios for AF by potential risk factor category, are
presented in Table 1. The final risk score model included the following variables: age, race,
height, systolic blood pressure, hypertension medication use, smoking status, precordial
murmur, LVH and LAE by ECG, diabetes, CHD, and HF. An interaction with race and
LVH, along with interactions of diabetes and CHD with age were also found. Table 2 lists
all risk factors in our risk score, along with points derived for each category. The oldest age
group (60–64) had the highest points assigned of any risk factor category. Blacks were given
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a point value of −4, indicating a lower risk of developing AF compared to whites. The
presence of ECG-diagnosed LVH increased the probability of developing AF in whites, but
not blacks. Also, diabetes and CHD were associated with AF in younger individuals, but not
among the oldest in our cohort.
The 10-year predicted probability of developing AF by total risk score is presented in Table
3. Individuals scoring ≤11 points had a 10-year predicted probability of developing AF of
<5%, whereas those scoring ≥19 points had >24% predicted probability of developing AF in
10 years.
Our final Cox regression model had an AUC of 0.78, indicating good discrimination. The
predicted number of AF events in the 10-year risk deciles were similar to the observed
events (Grønnesby-Borgan χ2=6.71, p=0.67). The point-based score had an AUC of 0.76,
which was statistically significantly lower than the Cox regression model. However, the
calibration of the point-based score was still good (Grønnesby-Borgan χ2=10.00, p=0.35).
Figure 1 depicts the observed and expected AF events by decile of predicted risk for both
the Cox regression model and the point-based score. The internal validation of our risk
score, based on 1000 bootstrap samples adjusted for optimism, revealed an AUC of 0.77
(95% CI, 0.75–0.78) for both the Cox regression model and for the point-based score,
indicating that our score would perform well in individuals from populations similar to the
ARIC cohort. Individual regression coefficients for the Cox regression model are reported in
Supplemental Table 1.
In addition to developing a risk score for AF in the ARIC cohort, we calculated scores for all
participants based on the Framingham Heart Study’s AF,2 CHD,18 and hard CHD19 risk
scores, as well as ARIC’s CHD risk score,20, 21 to determine whether these previously
published risk scores predict 10-year risk of AF as well as our AF risk score (Table 4). The
Framingham AF risk score predicted AF in the ARIC cohort (AUC=0.68), although it had
better discrimination for AF in whites compared to blacks. Finally, the 10-year probability
of developing AF was not predicted well by the Framingham CHD, Framingham hard CHD,
or ARIC CHD risk scores.
DISCUSSION
A 10-year risk score for incidence of AF was developed using risk factors commonly
measured in clinical practice in a prospective bi-racial community-based cohort. The risk
score had good discrimination, with AUC’s of 0.78 for the Cox regression model and 0.76
for the point-based score. As expected, in comparison to the Framingham AF risk score,2
our risk score better predicted who would develop AF in the ARIC cohort. In addition, the
prediction of AF using the Framingham18, 19 and ARIC20, 21 CHD risk scores was not good,
suggesting an AF-specific score is required to predict individual risk of AF.
Of interest, we found the incidence of AF was higher in whites compared to blacks. Yet,
most risk factors predicted AF similarly by race. Unlike the Framingham AF score, we did
not find P-R interval or BMI to predict AF risk. However, we additionally found height,
smoking status, ECG-diagnosed LVH and LAE, diabetes, and CHD to predict incidence of
AF. ECG-diagnosed LVH increased the risk of AF in whites, but did not appear to
contribute to 10-year incidence of AF in blacks. A clear explanation for this racial difference
is not evident; however, it is possible that the diagnosis of LVH by ECG results in more
false positives in blacks.24 It also appeared that diabetes and CHD contributed more to AF
risk in younger individuals. This may reflect more serious disease among individuals
diagnosed at younger ages or fewer competing risk factors, resulting in a greater proportion
of AF risk attributed to diabetes or CHD among young individuals.
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The Framingham 10-year risk score for CHD is widely used clinically and has been shown
to predict CHD well in other cohorts within the US, Australia, and New Zealand.25
However, we have shown that CHD risk scores are not effective at predicting AF risk. CHD
and AF share some common risk factors, such as hypertension, diabetes, and obesity, but
others, such as lipids, seem important in the development of CHD only. This highlights the
importance of a separate risk score to predict AF and, potentially, the need to develop
different preventive interventions.
Our study has several limitations. First, some AF events may have been missed because the
majority of events were ascertained by hospital discharge records. However, since incidence
rates of AF in ARIC are similar to those from other cohorts3 and associations of genetic risk
factors and AF in ARIC are similar to those found in cohorts relying more on study exam
ECGs for identification of AF events,26 we believe the underascertainment of AF events was
likely minimal. Second, our risk score was developed in a bi-racial cohort, and although our
risk score may be useful for black and white patients, it may not be useful for individuals of
other racial or ethnic backgrounds. Third, the limited age range of our population at
baseline, 45–64 years of age, limits the generalizability of our risk score to older individuals.
Fourth, only 1 measure of AF risk factors was used to develop our risk score.
Misclassification of exposure as risk factors change over follow-up may result in poorer
prediction of AF, and a risk score that accounts for changes in risk factors over time may
better predict AF risk. Fifth, the addition of genetic variants or biomarkers may have
improved the ability of our risk score to correctly classify those at greatest risk of
developing AF; however, we did not include these variables because they are less likely to
be consistently measured in primary care. Finally, the external validation of our risk score
using other cohorts may have provided better information on how well our risk score
predicts AF in other populations.
We have developed a clinical risk score for AF that may be appropriate for risk prediction in
blacks and whites. In addition, we have shown that the different pathophysiologies of AF
and CHD limit the usefulness of a CHD risk score at identifying individuals at higher risk of
AF. Thus, adoption of a new risk score for predicting incident AF, in addition to a CHD risk
score, may be clinically useful to identify those patients who are also at risk of developing
AF.
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Figure 1. Observed and Expected Atrial Fibrillation Events by Decile of Predicted Risk, ARIC
A: Cox regression model.
B: Point-based score.
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Table 1
Baseline Prevalences of Potential Atrial Fibrillation Risk Factors and Hazard Ratios for Atrial Fibrillation,
ARIC 10-Year Follow-Up
Risk Factor AF cases (N) Hazard Ratio (95% CI)*
Age (years)
 45 to <50 3897 (26.8%) 46 1.00 (ref)
 50 to <55 3771 (25.9%) 95 2.09 (1.47–2.97)
 55 to <60 3556 (24.5%) 129 2.91 (2.08–4.07)
 60 to 64 3322 (22.8%) 245 5.94 (4.34–8.15)
Race
 Black 3864 (26.6%) 83 0.60 (0.47–0.76)
 White 10682 (73.4%) 432 1.00 (ref)
Gender
 Male 6506 (44.7%) 325 1.92 (1.60–2.30)
 Female 8040 (55.3%) 190 1.00 (ref)
Body mass index (kg/m2)
 <20 469 (3.2%) 14 1.22 (0.70–2.13)
 20 to <25 4316 (29.7%) 121 1.00 (ref)
 25 to <30 5730 (39.4%) 200 1.12 (0.89–1.40)
 ≥>30 4026 (27.7%) 179 1.78 (1.41–2.24)
Height (cm)
 <164 4892 (33.6%) 114 1.00 (ref)
 164 to <173 4671 (32.1%) 142 1.28 (0.97–1.69)
 ≥173 4983 (34.3%) 259 1.92 (1.38–2.67)
Waist (cm)
 <88/102 (women/men) 6792 (46.7%) 209 1.00 (ref)
 ≥88/102 (women/men) 7751 (53.3%) 305 1.55 (1.29–1.86)
Systolic blood pressure (mmHg)
 <100 1315 (9.0%) 23 0.82 (0.53–1.28)
 100 to <120 6180 (42.5%) 153 1.00 (ref)
 120 to <140 4852 (33.4%) 197 1.42 (1.15–1.76)
 140 to <160 1648 (11.3%) 103 2.16 (1.67–2.79)
 >≥160 551 (3.8%) 39 2.63 (1.83–3.78)
Diastolic blood pressure (mmHg)
 <70 5326 (36.6%) 173 0.93 (0.75–1.15)
 70 to <80 5227 (35.9%) 178 1.00 (ref)
 80 to <90 2890 (19.9%) 114 1.24 (0.98–1.57)
 90 to <100 790 (5.4%) 34 1.53 (1.06–2.22)
 ≥100 312 (2.2%) 16 2.02 (1.20–3.41)
Hypertension medication use 4446 (30.6%) 276 2.55 (2.13–3.04)
Total cholesterol (mg/dL)
 <200 5410 (37.5%) 182 1.00 (ref)
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Risk Factor AF cases (N) Hazard Ratio (95% CI)*
 200 to <240 5432 (37.7%) 205 1.02 (0.83–1.24)
 > 240 3575 (24.8%) 127 0.95 (0.75–1.19)
LDL cholesterol (mg/dL)
 <100 2257 (15.9%) 64 1.00 (ref)
 100 to <130 4045 (28.5%) 137 1.03 (0.77–1.39)
 130 to <160 4239 (29.8%) 160 1.05 (0.78–1.40)
 160 to <190 2377 (16.7%) 94 1.03 (0.75–1.41)
 >190 1291 (9.1%) 40 0.88 (0.59–1.30)
HDL cholesterol (mg/dL)
 <40 3861 (26.8%) 215 1.76 (1.34–2.30)
 40 to <60 6730 (46.7%) 212 1.15 (0.89–1.49)
 >60 3828 (26.5%) 87 1.00 (ref)
Triglycerides (mg/dL)
 <150 14054 (97.4%) 489 1.00 (ref)
 150 to <200 227 (1.6%) 12 1.28 (0.72–2.27)
 >200 139 (1.0%) 13 2.61 (1.51–4.53)
Cholesterol medication use 422 (2.9%) 22 1.20 (0.78–1.84)
Sports Exercise
 <2.0 4102 (28.3%) 143 1.17 (0.77–1.78)
 2.0 to <3.0 6295 (43.4%) 222 1.06 (0.71–1.59)
 3.0 to <4.0 3408 (23.5%) 122 0.92 (0.61–1.40)
 >4.0 696 (4.8%) 27 1.00 (ref)
Smoking status
 Never 6059 (41.6%) 150 1.00 (ref)
 Former 4692 (32.3%) 202 1.27 (1.02–1.59)
 Current 3795 (26.1%) 163 1.69 (1.35–2.12)
Alcohol drinking status
 Never 3618 (25.0%) 101 1.00 (ref)
 Former 2743 (18.9%) 126 1.25 (0.95–1.63)
 Current 8132 (56.1%) 285 0.97 (0.76–1.24)
Heart rate (beats per minute)
 <60 3601 (24.8%) 136 1.00 (0.82–1.22)
 60 to <90 10588 (72.8%) 355 1.00 (ref)
 >90 357 (2.4%) 24 2.03 (1.34–3.06)
P-R Interval (ms)
 <160 6297 (43.3%) 200 1.00 (ref)
 160 to <200 6897 (47.4%) 247 1.04 (0.86–1.25)
 >200 1351 (9.3%) 68 1.41 (1.07–1.86)
Left ventricular hypertrophy 325 (2.2%) 27 2.73 (1.84–4.06)
Left atrial enlargement 5654 (38.9%) 277 1.61 (1.35–1.92)
Precordial murmur 1083 (7.5%) 69 1.92 (1.49–2.47)
Diabetes mellitus 1741 (12.0%) 110 1.87 (1.51–2.32)
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Risk Factor AF cases (N) Hazard Ratio (95% CI)*
Coronary heart disease† 688 (4.7%) 74 2.21 (1.71–2.84)
Heart failure 670 (4.6%) 64 3.03 (2.32–3.95)
*
Hazard ratios are adjusted for sex, race, and continuous age.
†
Coronary heart disease includes a history of myocardial infarction, myocardial infarction adjudicated from the baseline electrocardiogram, or
history of coronary bypass or angioplasty.
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Table 2
Points Assigned to Atrial Fibrillation Risk Factor Categories, ARIC
Risk Factor Points
Age (years)
 45 to <50 0
 50 to <55 3
 55 to <60 4






 164 to <173 1
 ≥173 4
Systolic blood pressure (mmHg)
 <100 −1
 100 to <120 0
 120 to <140 1
 140 to <160 2
 ≥160 3






Left atrial enlargement 2
Left ventricular hypertrophy
 white race 4
 black race 0
Diabetes mellitus
 age 45 to <50 4
 age 50 to <55 4
 age 55 to <60 1
 age 60 to 64 0
Heart failure 2
Coronary heart disease
 age 45 to <50 5
 age 50 to <55 3
 age 55 to <60 3
 age 60 to 64 0
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Table 3
Predicted 10-Year Risk of Atrial Fibrillation by Risk Score, ARIC
Score Predicted Risk
≤1 <1%
2 to 6 1%
7 to 8 2%
9 3%
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